Document Detail


Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis.
MedLine Citation:
PMID:  6359848     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The safety and efficacy of oral verapamil to control exercise tachycardia in 27 patients with atrial fibrillation and 3 with atrial flutter receiving digitalis was evaluated in a double-blind, randomized, crossover study. The heart rate in patients who received verapamil compared with placebo group was lower at rest (mean 69 +/- 13 versus 87 +/- 20 beats/min, p less than 0.01), as was the degree of tachycardia at the end of 3 minutes of a standardized exercise test (104 +/- 14 versus 136 +/- 23 beats/min, p less than 0.01). Doses of verapamil required to achieve suppression of tachycardia were 240 mg/day in 18 patients, 320 mg/day in 6 patients, and 480 mg/day in 3 patients. Only 3 patients complained of adverse effects from verapamil during the double-blind phase of the study. Two patients were discontinued from the study because of adverse reactions. No clinically significant changes during verapamil therapy were observed on the electrocardiogram, chest roentgenogram, echocardiogram or in the laboratory evaluation. Digoxin blood levels were higher in patients who received concomitant verapamil compared with placebo (1.23 +/- 0.59 versus 0.85 +/- 0.46 ng/ml, p less than 0.01), but no patient had signs or symptoms of digitalis toxicity. Thus, oral verapamil given in addition to digitalis is a safe and effective agent in the treatment of patients with chronic atrial fibrillation or flutter to decrease exercise-induced tachycardia.
Authors:
I P Panidis; J Morganroth; C Baessler
Related Documents :
12877698 - Paroxysmal atrial fibrillation: ectopic atrial activity and prevalence of severely symp...
19910318 - Transthoracic second harmonic two- and three-dimensional echocardiography for detection...
18373138 - Application of a decision support tool for anticoagulation in patients with non-valvula...
9714488 - Transvasal closure of interatrial defects using the babic double-umbrella occluder system.
3909278 - Parasympathetic activity assessed by diving reflex and by airway response to methacholi...
21048198 - Novel csf biomarkers for frontotemporal lobar degenerations.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  52     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1983 Dec 
Date Detail:
Created Date:  1984-01-07     Completed Date:  1984-01-07     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1197-201     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Atrial Fibrillation / complications,  drug therapy*
Atrial Flutter / complications,  drug therapy
Chronic Disease
Clinical Trials as Topic
Digitalis*
Digoxin / blood
Double-Blind Method
Female
Humans
Male
Middle Aged
Physical Exertion / drug effects*
Placebos
Plants, Medicinal*
Plants, Toxic*
Random Allocation
Tachycardia / drug therapy*,  etiology
Verapamil / administration & dosage,  adverse effects*
Chemical
Reg. No./Substance:
0/Placebos; 20830-75-5/Digoxin; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestiv...
Next Document:  Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia.